James N. Kochenderfer, M.D.
James N. Kochenderfer, M.D.
Investigator

Center for Cancer Research
National Cancer Institute

Building 10 - CRC - Room 3-3888
Bethesda, MD 20892
301-594-5340

Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.

Areas of Expertise
1) Chimeric Antigen Receptors 2) Treatment of Lymphoma, Leukemia, and Multiple Myeloma 3) T-cell immunology 4) Gene therapy 5) Immunotherapy 6) Hematopoietic stem cell transplantation

Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies. T cells normally play a critical role in fighting infections. Under certain circumstances, T cells can exert a powerful and specifically-targeted anti-malignancy effect. Dr. Kochenderfer's current laboratory work involves genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.

Scientific Focus Areas:
Clinical Research, Immunology
Selected Recent Publications
  1. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.
    Blood. 116: 3875-86, 2010. [ Journal Article ]
  2. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.
    Blood. 116: 4099-102, 2010. [ Journal Article ]
  3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
    Blood. 119: 2709-20, 2012. [ Journal Article ]
  4. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
    Clin. Cancer Res. 19: 2048-60, 2013. [ Journal Article ]
  5. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
    Blood. 122: 4129-39, 2013. [ Journal Article ]

Dr. Kochenderfer is a clinician and translational researcher in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI). Dr. Kochenderfer conducts research aimed at developing new T-cell therapies for lymphoma and leukemia. His clinical expertise lies in the areas of hematopoietic stem cell transplantation and hematologic malignancies. Dr. Kochenderfer received his M.D. from West Virginia University in 1995, and he completed clinical training in internal medicine at Vanderbilt University. He completed oncology and hematology fellowships at the University of Texas M.D. Anderson Cancer Center and at Baylor College of Medicine. He completed further training in tumor immunology and stem cell transplantation at the NCI prior to assuming his current position as an Assistant Clinical Investigator.

Name Position
Leah Alabanza Postdoctoral Fellow (Visiting)
Claudia Geldres Postdoctoral Fellow (CRTA)
Victoria Shi Research Biologist

Summary

Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.

Areas of Expertise
1) Chimeric Antigen Receptors 2) Treatment of Lymphoma, Leukemia, and Multiple Myeloma 3) T-cell immunology 4) Gene therapy 5) Immunotherapy 6) Hematopoietic stem cell transplantation

Clinical Trials

Research

Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies. T cells normally play a critical role in fighting infections. Under certain circumstances, T cells can exert a powerful and specifically-targeted anti-malignancy effect. Dr. Kochenderfer's current laboratory work involves genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.

Scientific Focus Areas:
Clinical Research, Immunology

Publications

Selected Recent Publications
  1. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.
    Blood. 116: 3875-86, 2010. [ Journal Article ]
  2. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.
    Blood. 116: 4099-102, 2010. [ Journal Article ]
  3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
    Blood. 119: 2709-20, 2012. [ Journal Article ]
  4. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
    Clin. Cancer Res. 19: 2048-60, 2013. [ Journal Article ]
  5. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
    Blood. 122: 4129-39, 2013. [ Journal Article ]

Biography

Dr. Kochenderfer is a clinician and translational researcher in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI). Dr. Kochenderfer conducts research aimed at developing new T-cell therapies for lymphoma and leukemia. His clinical expertise lies in the areas of hematopoietic stem cell transplantation and hematologic malignancies. Dr. Kochenderfer received his M.D. from West Virginia University in 1995, and he completed clinical training in internal medicine at Vanderbilt University. He completed oncology and hematology fellowships at the University of Texas M.D. Anderson Cancer Center and at Baylor College of Medicine. He completed further training in tumor immunology and stem cell transplantation at the NCI prior to assuming his current position as an Assistant Clinical Investigator.

Team

Name Position
Leah Alabanza Postdoctoral Fellow (Visiting)
Claudia Geldres Postdoctoral Fellow (CRTA)
Victoria Shi Research Biologist